DOI: 10.1111/odi.13776

LETTER TO THE EDITOR



Careful use of clonazepam and alpha lipoid acid in burning mouth syndrome treatment

Dear Editor,

We read the article regarding burning mouth syndrome (BMS) and clonazepam titled "Treatment outcomes and related clinical characteristics in patients with burning mouth syndrome" from Dr. Kim of Seoul National University, South Korea, with maximum interest (Kim et al., 2020). They evaluated the treatment outcomes of BMS treatment. The authors prescribed clonazepam for long term, and they offered combination therapy of clonazepam and alpha lipoid acid (ALA) for BMS patients, which brought favorable results. However, the article would need more attention to the risk of side effects of clonazepam and ALA.

Review articles provided many treatment options for BMS, including clonazepam, ALA, and some antidepressants (Jaaskelainen & Woda, 2017). Among rare randomized controlled studies conducted regarding BMS treatment, clonazepam and ALA showed effectiveness but the problem is the short-period follow-up. In terms of the first-line medication for BMS, it may vary from country to country. In particular, Japanese doctors have prescribed tricyclic antidepressants since half century ago (Tu et al., 2019). In France, the prescription of clonazepam is limited to only neurologists and pediatricians due to some concerns about its side effects and antidepressants are commonly used (Fenelon et al., 2017). Instead, in Brazil, benzodiazepines could be used in common prescription. In Iran, antidepressants, anticonvulsant, and topical clonazepam are used (Derafshi et al., 2019).

Even though benzodiazepines have advantages in reduction in stress and improvements in sleep for short term (4–12 weeks), they would produce risks and harms in long-term prescription (DeKosky & Williamson, 2020). In fact, clonazepam would induce many side effects such as drowsiness, cognitive impairment, and intestinal motor disturbances (Jaaskelainen & Woda, 2017), or in a worst scenario might lead to dependence. The National Institute of Health and Care Excellence (NICE) recommended that benzodiazepines should be prescribed at lowest dose for minimum period. However, in a 1-year follow-up BMS study, ethyl loflazepate, a long-acting benzodiazepine, is promising and better choice since no incidence of dependence was reported (Paudel et al., 2020).

In terms of ALA, it was used originally for diabetes. It has been used for dieting, diabetic neuropathy, or antioxidant supplement in many countries. However, ALA possesses risk of hypoglycemia (Golbidi et al., 2011). Further, ALA can induce autoimmune syndrome in patients with some types of HLA (DRB1*0406, high prevalence in East Asian populations) (Uchigata, 2007). Altogether, the Ministry of Health, Labor, and Welfare in Japan has remarks of hypoglycemia induced by ALA on its website.

There is undeniable that every medication has its unwanted side effects besides the desired effectiveness. In some cases, the adverse effects could lead to serious outcomes. Considering there will be more elderly patients with BMS in near future (Suga et al., 2018), and this population, who are often prescribed polypharmacy, will be most vulnerable by side effects. Careful selection, monitoring, and dose titration therefore would lead to successful prescription. In pursuit of treatment efficacy, we should pay attention to a "not-solittle" side effect of medications used in BMS treatment. Otherwise, safe and efficient new treatment option or refined treatment regimen needs to be sought.

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

AUTHOR CONTRIBUTIONS

Takayuki Suga: Writing-original draft. T.H Trang Tu : Writing-review & editing. Akira Toyofuku: Supervision; Writing-review & editing. Takahiko Nagamine: Supervision; Writing-review & editing.

FUNDING INFORMATION

This work was supported in part by JSPS KAKENHI Grant Number 19K10328 to Prof. Toyofuku.


PEER REVIEW

The peer review history for this article is available at https://publo ns.com/publon/10.1111/odi.13776.

Date of submission: Jan 4, 2021

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2021 The Authors. Oral Diseases published by Wiley Periodicals LLC

ORAL DISEASES



¹Department of Psychosomatic Dentistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan ²Department of Psychiatric Internal Medicine, Sunlight Brain Research Center, Yamaguchi, Japan

Correspondence

Takayuki Suga, Department of Psychosomatic Dentistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan. Email: suga.ompm@tmd.ac.jp

ORCID

 Takayuki Suga
 https://orcid.org/0000-0001-7907-2127

 Trang T. H. Tu
 https://orcid.org/0000-0002-6062-4603

 Takahiko Nagamine
 https://orcid.org/0000-0002-0690-6271

 Akira Toyofuku
 https://orcid.org/0000-0002-9498-3014

REFERENCES

- DeKosky, S. T., & Williamson, J. B. (2020). The long and the short of benzodiazepines and sleep medications: Short-term benefits, longterm harms? Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics, 17(1), 153–155. https://doi. org/10.1007/s13311-019-00827-z
- Derafshi, R., Rezazadeh, F., Ghapanchi, J., Basandeh Sharif, D., & Farzin, M. (2019). Prevalence of chronic orofacial pain in elderly patients referred to Shiraz dental school from 2005 to 2017. Anesthesiology and Pain Medicine, 9(6), e91182. https://doi.org/10.5812/aapm.91182

Fenelon, M., Quinque, E., Arrive, E., Catros, S., & Fricain, J. C. (2017). Painrelieving effects of clonazepam and amitriptyline in burning mouth syndrome: A retrospective study. *International Journal of Oral and Maxillofacial Surgery*, 46(11), 1505–1511. https://doi.org/10.1016/j. ijom.2017.03.032

- Golbidi, S., Badran, M., & Laher, I. (2011). Diabetes and alpha lipoic acid. Frontiers in Pharmacology, 2, 69. https://doi.org/10.3389/ fphar.2011.00069
- Jaaskelainen, S. K., & Woda, A. (2017). Burning mouth syndrome. Cephalalgia, 37(7), 627–647. https://doi.org/10.1177/0333102417 694883
- Kim, M. J., Kim, J., & Kho, H. S. (2020). Treatment outcomes and related clinical characteristics in patients with burning mouth syndrome. *Oral Diseases*. https://doi.org/10.1111/odi.13693
- Paudel, D., Utsunomiya, M., Yoshida, K., Giri, S., Uehara, O., Matsuoka, H., Chiba, I., Toyofuku, A., & Abiko, Y. (2020). Pharmacotherapy in relieving the symptoms of burning mouth syndrome: A 1-year follow-up study. Oral Diseases, 26(1), 193–199. https://doi.org/10.1111/ odi.13226
- Suga, T., Watanabe, T., Aota, Y., Nagamine, T., & Toyofuku, A. (2018). Burning mouth syndrome: The challenge of an aging population. *Geriatrics & Gerontology International*, 18(12), 1649–1650. https://doi. org/10.1111/ggi.13548
- Tu, T. T. H., Takenoshita, M., Matsuoka, H., Watanabe, T., Suga, T., Aota, Y., Abiko, Y., & Toyofuku, A. (2019). Current management strategies for the pain of elderly patients with burning mouth syndrome: A critical review. *BioPsychoSocial Medicine*, 13, 1. https://doi.org/10.1186/ s13030-019-0142-7
- Uchigata, Y. (2007). The novel agent, alpha lipoic acid, can cause the development of insulin Autoimmune Syndrome. *Internal Medicine*, 46(17), 1321–1322. https://doi.org/10.2169/internalmedicine.46.0221

How to cite this article: Suga T, Tu TTH, Nagamine T, Toyofuku A. Careful use of clonazepam and alpha lipoid acid in burning mouth syndrome treatment. *Oral Dis.* 2022;28: 846–847. https://doi.org/10.1111/odi.13776